SereNeuro Therapeutics has developed a breakthrough innovation that enables non-opioid treatment for pain at scale. Using a proprietary sensory neuron differentiation protocol and cutting-edge gene editing, SereNeuro has, for the first time ever, generated scalable and purifiable subsets of mature human sensory neuronal cells to decipher the functional heterogeneity of human pain perception leading to two promising biologic therapies for pain.